Patent details

EN | LT

Supplementary protection

LT - Antikūno molekulės, turinčios specifiškumą žmogaus auglio nekrozės faktoriui alfa ir jų panaudojimas

EN - ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN TUMOR NECROSIS FACTOR ALPHA, AND USE THEREOF

SPC
(11)	Number of the document	C 1287140
(68)	Number of the document	1287140
(21)	Application number for Supplementary Protection Certificate	PA 2010 006
(22)	Date of filing the application	2010-03-24
(41)	Date of publication of the application	2010-04-26
	Date of publication of SPC	2011-01-25
(24)	Date of coming into effect of SPC	2021-06-06

Applicant
(71)	UCB Pharma, S.A., Allée de La Recherche 60, 1070 Brussels, BE

Grantee
(73)	UCB Pharma, S.A., Allée de La Recherche 60, 1070 Brussels, BE

Attorney or representative
(74)	Marius JAKULIS - JASON, AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius, LT

Number, date and code of the country of origin of the first authorization to place the medicinal or plant protection product on the market within regional economic community
(93)	EU/1/09/544/001, 2009-10-01 EU/1/09/544/002, 2009-10-01

Calculated date of expiry of the SPC
(94)	2024-10-06

Name of the product protected by the basic patent
(95)	Certolizumabum pegolum

Last renewal fee
	Payment date	Validity (years)	Amount
	2024-05-09		347.00 EUR

Legal status
	SPC expired